Florian Ludwig, Ph.D., is a medical device professional with 20+ years experience in biophysical research and medical device development. He serves as an investment director at Thuja Capital Management, a European healthcare investor focused on bringing meaningful innovation to patients. Structured to invest in innovative medical devices, therapeutics and diagnostics, Thuja Capital invests in disruptive concepts aiming to improve patient outcomes and contribute to a sustainable healthcare system. Thuja currently has over €50 million under management, with active investments in medtech, biotech and nutraceuticals. Prior to joining Thuja Capital, Florian has led and served on innovation and development teams in global organizations (Guidant, Abbott Vascular, Covidien) and in start-ups (Ventrigraft, Ventrica, ROX Medical, Direct Flow Medical). Drawing on a combination of scientific understanding, market insight and direct field experience, Florian has provided leadership to innovative therapy development programs for heart failure, structural heart, cardiovascular, pulmonary and orthopedic indications.
Florian holds a Diplom and a doctorate degree in physics from the Technical University of Munich, Germany, gained in research collaborations with Duke University, USA, and the University of British Columbia, Canada. He is an author on over 40 issued patents.
About Thuja Capital
Thuja Capital is an independent venture capital firm investing in early-stage medical product companies in the Netherlands and Belgium. Our focus is on scaleable products meant for diagnosis, cure, care and prevention, that require (clinical) validation to enable a health claim, and that have the potential to improve quality and/or lower healthcare costs. Apart from providing capital, we leverage our network and provide hands-on support to the companies we invest in.